VisionGate’s Cell-CT™ Platform Uses 3D Cell Morphometry and Artificial Intelligence to Detect an Immunotherapy Predictive Biomarker and Cancer-Associated Cells that have undergone Malignancy Associated Change (MAC) from Liquid Biopsy
24 sept. 2018 06h00 HE
|
VisionGate, Inc.
Seattle, WA, Sept. 24, 2018 (GLOBE NEWSWIRE) -- VisionGate, a clinical stage oncology pharmaceutical and diagnostics company announces two peer-reviewed poster presentations at the International...
VisionGate Lung Cancer 3D Cellular Imaging Research to be Featured as a Late-Breaking Abstract at the AACR Annual Meeting 2018
12 avr. 2018 13h46 HE
|
VisionGate, Inc.
SEATTLE, WA, April 12, 2018 (GLOBE NEWSWIRE) -- VisionGate, Inc., a clinical stage oncology pharmaceutical and diagnostics company, is pleased to announce that new lung cancer 3D cellular imaging...
VisionGate is Leveraging the Cell-CT™ Platform to Expand Cancer Diagnostics Services, Biopharmaceutical Services and Cancer Prevention Medicines
05 avr. 2018 14h03 HE
|
VisionGate, Inc.
SEATTLE, WA, April 05, 2018 (GLOBE NEWSWIRE) -- VisionGate, a clinical stage oncology pharmaceutical and diagnostics company, is pleased to announce today the advancement of its breakthrough...